by Raynovich Rod | Oct 25, 2020 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Macro
Update-3 10/29. 1p EDT…Earnings reports stabilize biopharma stocks. Vaccine stocks strong. Gilead Sciences (GILD) beats but lowers guidance.Needs clinical news on deals. Stock lower. Amgen (AMGN) holds $216 after beat, osteoporosis drug opportunity. Early...
by Raynovich Rod | Oct 2, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Update-2 10/4 Broad Rally day: all major averages up 1.4%, NAZ at 7982. Risk back on. But biotech lags major indices IBB up 0.75%, XBI up 0.21% to $76.82. Better trade for biotech has been large caps: ABBV, AMGN, MRK,RHHBY VRTX. Mid-cap movers: BLUE up 3.97%, GWPH up...
by Raynovich Rod | Jan 8, 2019 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1…1/21/19 Liquid Biopsy I attended a Panel Session on Cancer Liquid Biopsy and although progress is being made on molecular diagnostics there are no newsworthy breakthroughs nor actual data showing a hard timeline. Here is an article from BIO 2016. There...
by Raynovich Rod | Jun 8, 2018 | Biopharmaceuticals
ASCO 2018 Rally Part 2: Traders Take Profits on Nice Gains Biotech Indices and ETFs Show Gains YTD: FBIOX up 8% YTD, IBB up 3.13%, XBI up 9.34% The ASCO 2018 biotech rally was almost according to the script-nice gains leading up to the meeting followed by momentum...
by Raynovich Rod | Jan 11, 2018 | Clinical Diagnostics and Tools
Key Trends in Diagnostics and Lifesciences: Promise, Reality Reimbursement Panel Moderator: Ken Bahk, Three Lake Partners. Panelists- Nathan Ledeboer, Medical College of Wisconsin,Victoria Pratt, Indiana University School of Medicine, Nick Papadopolous, Johns Hopkins...
by Raynovich Rod | Oct 21, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
CLIA Labs Offer Liquid Biopsy Tests for Cancer and Precision Medicine We attended presentations from two emerging companies developing molecular diagnostics platforms focused in cancer.Their mission is to develop cost-effective, non-invasive diagnostic assays and...
by Raynovich Rod | Jun 5, 2016 | Biopharmaceuticals
Pre-ASCO rally-Three Weeks of gains= 8-15% Every year the ASCO Meeting excites investors because of clinical data being presented on a huge pipeline of oncology products. High expectations have already delivered an ASCO rally so now can the actual clinical data...